Comparison of magnetic resonance spectroscopy and positron emission tomography in detection of tumor recurrence in posttreatment of glioma: A diagnostic meta-analysis

Asia-Pacific Journal of Clinical Oncology

Volumn 11, Issue 2, 2015, Pages 97-105

  Wang, Xiaoyue ^a   Hu, Xudong ^a   Xie, Peng ^a   Li, Wanhu ^a   Li, Xiaoling ^a   Ma, Li ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Glioma; Magnetic resonance spectroscopy; Meta analysis; Positron emission tomography; Recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE C 11;

CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GLIOMA; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION NECROSIS; REVIEW; SENSITIVITY AND SPECIFICITY; BRAIN NEOPLASMS; FEMALE; METABOLISM; PROCEDURES; TUMOR RECURRENCE;

BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY;

EID: 84928792726     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12202     Document Type: Review

References (36)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2005-2009. Neuro-Oncol 2012; 14 (Suppl 5): v1-1v49.
2. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453-461.
3. Patronas NJ, Di CG, Brooks RA etal. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144: 885-889.
4. la FC, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro-Oncol 2011; 13: 806-819.
5. Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 2009; 6: 648-657.
6. Enslow MS, Zollinger LV, Morton KA etal. Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 2012; 37: 854-861.
7. Santra A, Kumar R, Sharma P etal. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Eur J Radiol 2012; 81: 508-513.
8. Tripathi M, Sharma R, Varshney R etal. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 2012; 37: 158-163.
9. Li DL, Xu YK, Wang QS, Wu HB, Li HS. (1)(1)C-methionine and (1)(8)F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Chin Med J (Engl) 2012; 125: 91-96.
10. Ozsunar Y, Mullins ME, Kwong K etal. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging. Acad Radiol 2010; 17: 282-290.
11. Prat R, Galeano I, Lucas A etal. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas. J Clin Neurosci 2010; 17: 50-53.
12. Gomez-Rio M, Rodriguez-Fernandez A, Ramos-Font C, Lopez-Ramirez E, Llamas-Elvira JM. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging 2008; 35: 966-975.
13. Van Laere K, Ceyssens S, Van Calenbergh F etal. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005; 32: 39-51.
14. Belohlavek O, Klener J, Vymazal J, Dbaly V, Tovarys F. The diagnostics of recurrent gliomas using FDG-PET: still questionable. Nucl Med Rev Cent East Eur 2002; 5: 127-130.
15. Stokkel M, Stevens H, Taphoorn M, Van Rijk P. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera-a pilot study. Nucl Med Commun 1999; 20: 411-417.
16. Bader JB, Samnick S, Moringlane JR etal. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 1999; 26: 144-151.
17. Thompson TP, Lunsford LD, Kondziolka D. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotact Funct Neurosurg 1999; 73: 9-14.
18. Nakajima T, Kumabe T, Kanamori M etal. Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography. Neurol Med Chir (Tokyo) 2009; 49: 394-401.
19. Terakawa Y, Tsuyuguchi N, Iwai Y etal. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008; 49: 694-699.
20. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T. Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 1998; 38: 342-347, discussion 347-48.
21. Amin A, Moustafa H, Ahmed E, El-Toukhy M. Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results. J Neurooncol 2012; 106: 579-587.
22. Fink JR, Carr RB, Matsusue E etal. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging 2012; 35: 56-63.
23. Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR. Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010; 52: 297-306.
24. Peca C, Pacelli R, Elefante A etal. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis. Clin Neurol Neurosurg 2009; 111: 331-334.
25. Zeng QS, Li CF, Liu H, Zhen JH, Feng DC. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 2007; 68: 151-158.
26. Palumbo B, Lupattelli M, Pelliccioli GP etal. Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy. Q J Nucl Med Mol Imaging 2006; 50: 88-93.
27. Plotkin M, Eisenacher J, Bruhn H etal. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J Neurooncol 2004; 70: 49-58.
28. Rabinov JD, Lee PL, Barker FG etal. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002; 225: 871-879.
29. Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol 2012; 10: 240-246.
30. Jahangiri A, Aghi MK. Pseudoprogression and treatment effect. Neurosurg Clin N Am 2012; 23: 277-287, viii-ix.
31. Hygino DCLC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011; 32: 1978-1985.
32. Siu A, Wind JJ, Iorgulescu JB, Chan TA, Yamada Y, Sherman JH. Radiation necrosis following treatment of high grade glioma - a review of the literature and current understanding. Acta Neurochir (Wien) 2012; 154: 191-201, discussion 201.
33. Kracht LW, Miletic H, Busch S etal. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004; 10: 7163-7170.
34. Ogawa T, Kanno I, Shishido F etal. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C- methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991; 32: 197-202.
35. Zeng QS, Li CF, Zhang K, Liu H, Kang XS, Zhen JH. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007; 84: 63-69.
36. Kozic D, Ostojic J, Bjelan M, Koprivsek K. The role of MR spectroscopy in neurooncology. Prilozi 2012; 33: 425-433.